Tags: GPT‑Rosalind

Kevin Weil, OpenAI's former chief product officer who recently led the company’s new AI workspace for scientists called Prism, announced his exit on Friday. The departure coincides with OpenAI’s decision to dissolve Prism, folding its roughly 10‑person team into the Codex division. The move is part of a broader effort to streamline product offerings and focus on enterprise and coding tools as the company prepares for an IPO. OpenAI also confirmed the launch of GPT‑Rosalind, a suite of models aimed at accelerating life‑science research. Read more

OpenAI unveiled GPT‑Rosalind, its first large‑language model built specifically for life‑science research. Named for DNA pioneer Rosalind Franklin, the system is designed to help scientists sort through massive data sets, generate hypotheses and speed the development of new medicines. OpenAI says the model can cut the 10‑ to 15‑year timeline typical for U.S. drug approval by improving target selection and experiment design. Available now as a research preview through a trusted‑access platform, GPT‑Rosalind also includes safeguards against misuse, as the company faces a copyright lawsuit from Ziff Davis. Read more

OpenAI announced the departures of Kevin Weil, who headed its science research unit, and Bill Peebles, the creator of the AI video tool Sora. The exits come as the company trims “side quests” and concentrates resources on enterprise AI and its upcoming super‑app. Weil’s team had just released GPT‑Rosalind, a model aimed at accelerating drug discovery, while Peebles cited the need for research space away from the main product roadmap. Read more

OpenAI has unveiled GPT‑Rosalind, a large language model tuned specifically for biology. The new system aims to curb the over‑enthusiasm and sycophancy that have plagued earlier models, offering more skeptical, fact‑checked responses on drug targets and other scientific queries. Access is restricted to U.S. entities through a trusted‑deployment program, with a broader Life Sciences Research Plugin slated for later release. OpenAI cites safety concerns, including the risk of the model being used to optimize harmful viruses, as the reason for the limited rollout. Read more